Compare SANG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANG | SPRO |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.0M | 136.7M |
| IPO Year | 2021 | 2017 |
| Metric | SANG | SPRO |
|---|---|---|
| Price | $5.06 | $2.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 4.1K | ★ 318.6K |
| Earning Date | 02-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,360,000.00 | $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.08 | $0.51 |
| 52 Week High | $7.99 | $3.22 |
| Indicator | SANG | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 47.73 |
| Support Level | $5.03 | $2.26 |
| Resistance Level | $5.42 | $2.38 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 42.28 | 54.76 |
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.